OCT Clinical

OCT Clinical is a contract research organization established in 2005 that has merged with Palleos Healthcare GmbH and now operates under the Palleos Healthcare brand. The company specializes in conducting clinical trials across Central and Eastern Europe, with operations in 21 countries including Germany, Poland, Spain, Bulgaria, Ukraine, Turkey, and Russia. Since its founding, OCT Clinical has completed over 300 studies across 29 therapeutic areas and enrolled 58,937 patients.

The organization provides full-service CRO capabilities for Phase I-IV and bioequivalence studies, offering services from study design and regulatory support through site management, data management, and biostatistics. OCT Clinical maintains a network of over 2,100 research sites across its operational footprint and has developed particular expertise in rescue studies for trials that have encountered obstacles. The company is an official member of the European CRO Federation (EUCROF) and delivers data acceptable to both EMA and FDA regulatory standards.

Notable achievements include completing patient recruitment seven months ahead of schedule for a Samsung Bioepis lung cancer study and demonstrating enrollment rates up to four times faster than other regions. The company has worked with major pharmaceutical clients including Pfizer, Novartis, and Samsung Bioepis across therapeutic areas with particular strength in oncology, respiratory diseases, gastroenterology, neurology, and rheumatology.

Organizations should consider OCT Clinical when geographic expansion into Central and Eastern Europe is strategically important for clinical development programs. The company's value proposition centers on accelerated patient recruitment in regions with large treatment-naïve populations and established research infrastructure that meets Western regulatory standards.

Sponsors facing enrollment challenges or timeline pressures will benefit from OCT Clinical's rescue study expertise and proven ability to complete recruitment ahead of schedule. The full-service model and deep regional relationships provide operational efficiency for companies without existing Eastern European capabilities, while the therapeutic breadth accommodates diverse development portfolios.

OCT Clinical operates exclusively within the pharmaceutical and biotechnology clinical research sector, providing specialized services for drug development trials from early-stage through post-marketing studies. The company's healthcare focus encompasses regulatory compliance with EMA and FDA standards, Good Clinical Practice (GCP) adherence, and pharmacovigilance services specific to pharmaceutical development.

Therapeutic expertise spans 29 healthcare verticals with particular depth in oncology (breast, lung, colorectal, prostate cancers), respiratory diseases (asthma, COPD, tuberculosis), gastroenterology (inflammatory bowel disease, Crohn's disease), neurology (Alzheimer's, multiple sclerosis), rheumatology, and infectious diseases. The company's clinical trial infrastructure and site networks are purpose-built for pharmaceutical research within these healthcare specializations.

Mid-sized to large pharmaceutical and biotechnology companies conducting Phase I-IV clinical trials who need to expand into Central and Eastern European markets. Organizations seeking cost-effective patient recruitment with faster enrollment timelines while maintaining regulatory compliance for EMA and FDA submissions. Companies with development programs in oncology, respiratory diseases, neurology, or gastroenterology where OCT Clinical has established therapeutic expertise and site networks.